Abstract
Mast cells are key as effector cells in the early phase allergic inflammation and in diverse immunological and pathological processes. Forsythia fructus (F. fructus) has used as a traditional medicine for inflammatory diseases. In the present study, we determined the effect of F. fructus extracts on compound 48/80-induced paw oedema and vascular permeability in vivo. In addition, we investigated in vitro whether F. fructus has inhibitory effects on compound 48/80-induced histamine releases from rat peritoneal mast cells (RPMC), and on phorbol 12-myristate 13-acetate (PMA) plus A23187-induced tumor necrosis factor-α (TNF-α) releases from human mast cells (HMC-1). In mice orally administrered F. fructus (100 μg/g) for 1 h, compound-48/80-induced oedema and vascular permeability were significantly reduced rather than those receiving intravenous injection of ketotifen, mast cell stabilizer. F. fructus dose-dependently inhibited the histamine release induced by compound 48/80 from RPMCs. Moreover, F. fructus had no cytotoxic effects on cell viability and had inhibitory effects on TNF-α secretion from HMC-1. These results suggest that F. fructus is a potential herb medicine for treatment of inflammatory diseases through downmodulating mast cell activation.
Similar content being viewed by others
References
Ozaki, Y., J. Rui, and Y. T. Tang. 2000. Antiinflammatory effect of Forsythia suspense V(AHL) and its active principle. Biol. Pharm. Bull. 23:356–357.
Lee, E. B. and H. J. Keum. 1988. Pharmacological studies on Forsythia fructus. Kor. J. Pharmacognosy. 19:262–269.
Lentsch, A. B. and P. A. Ward. 2000. Regulation of inflammatory vascular damage. J. Pathol. 190:343–348.
Metcalfe, D. D., D. Baram, and Y. A. Mekori. 1999. Mast cells. Physiol. Rev. 77:1033–1079.
Pearce, F. L. 1989. Mast cells: Function, differentiation and activation. Curr. Opin. Immunol. 1:630–636.
Murrant, T. and D. Bihari. 2000. Anaphylaxis and anaphylactoid reactions. Int. J. Clin. Pract. 54:322–328.
Krishnaswamy, G., J. Kelley, D. Johnson, G. Youngberg, W. Stone, S. K. Huang, J. Bieber, and D. S. Chi. 2001. The human mast cell: Functions in physiology and disease. Front. Biosci. 6:1109–1127.
Bradding, P. and S. T. Holgate. 1999. Immunopathology and human mast cell cytokines. Crit. Rev. Oncol. Hematol. 31:119–133.
White, M. 1999. Mediators of inflammation and the inflammatory process. J. Allergy Clin. Immunol. 103:S378-S381.
Guo, Y., T. Mochizuki, E. Morii, Y. Kitamura, and K. Maeyama. 1997. Role of mast cell histamine in the formation of rat paw edema: A microdialysis study. Eur. J. Pharmacol. 331:237–243.
Assanasen, P. and R. M. Naclerio. 2002. Antiallergic anti-inflammatory effects of H1-antihistamines in humans. Clin. Allergy Immunol. 17:101–139.
Kobayashi, H., T. Ishizuka, and Y. Okayama. 2000. Human mast cells and basophils as sources of cytokines. Clin. Exp. Allergy. 30:1205–1212.
Männel, D. N. and B. Echtenacher. 2000. TNF in the inflammatory response. Chem. Immunol. 74:141–161.
Meng, H., M. G. Tonnesen, M. J. Marchase, R. A. Clark, W. F. Bahou, and B. L. Gruber. 1995. Mast cells are potent regulator endothelial cell adhesion molecule ICAM-1 and VCAM-1 expression. J. Cell. Physiol. 165:40–53.
Iuvone, T., R. van den Bossche, F. D'Acquisto, R. Carnuccio, and A. G. Herman. 1999. Evidence that mast cell degranulation, histamine and tumor necrosis factor α release occur in LPS-induced plasma leakage in rat skin. Br. J. Pharmacol. 128:700–704.
Queralt, M., P. Brazis, M. Merlos, F. de Mora, and A. Puigdemont. 2000. In vitro inhibitory effect of rupatadine on histamine and TNF-α release from dispersed canine skin mast cells and the human mast cell line HMC-1. Inflamm. Res. 49:355–360.
Sawynok, J., A. Reid, and X. J. Lie. 2000. Involvement of mast cells, sensory afferents and sympathetic mechanisms in paw oedema induced by adenosine A1 and A2B/3receptor agonists. Eur. J. Pharmacol. 395:47–50.
Linardi, A., S. K. Costa, G. R. da Silva, and E. Antunes. 2000. Involvement of kinins, mast cells and sensory neurons in the plasma exudation and paw oedema induced by staphylococcal enterotoxin B in the mouse. Eur. J. Pharmacol. 399:235–242.
Bronner, C., C. Wiggins, D. Monte, F. Marki, A. Capron, Y. Landry, and R. C. Franson. 1987. Compound 48/80 is a potent inhibitor of phospholipase C and a dual modulator of phospholiphase A2 from human platelet. Biochim. Biophys. Acta 920:301–305.
Grant, S. M., K. L. Goa, A. Fitton, and E. M. Sorkin. 1990. Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs 40:412–448.
Hong, S. H., M. S. Kim, J. Y. Lee, C. Y. Hwang, S. H. Baek, D. S. Han, W. Y. Jung, S. B. Seo, T. Kajiuchi, and H. M. Kim. 2001. Novel finding in inhibition of mast cell-dependent immediate-type coetaneous reactions by Gahmi-Shini-San. Clin. Chim. Acta 309:85–90.
Yi, J. M., M. S. Kim, S. W. Seo, K. N. Lee, C. S. Yook, and H. M. Kim. 2001. Acanthopanax senticosus root inhibits mast cell-dependent anaphylaxis. Clin. Chim. Acta. 312:163–168.
Kim, M. S., W. K. Lim, J. G. Cha, N. H. An, S. J. Yoo, J. H. Park, H. M. Kim, and Y. M. Lee. 2001. The activation of PI 3-K and PKC-ζ in PMA-induced differentiation of HL-60 cells. Cancer Lett. 171:79–85.
Furitsu, T., T. Tsujimura, T. Tono, H. Ikeda, H. Kitamura, U. Koshimizu, H. Sigahara, J. H. Butterfield, L. K. Ashman, Y. Kanayama, Y. Matsuzawa, Y. Kitamura, and Y. Kanakura. 1993. Identification of mutations in the coding sequence of the photooncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92:1736–1744.
Nilsson, G., T. Blom, M. Kusche-Gullberg, L. Kjellén, J. H. Butterfield, C. Sundström, K. Nilsson, and L. Hellman. 1994. Phenotypic characterization of the human mast-cell line HMC-1. Scand. J. Immunol. 39:489–498.
Möller, A., B. M. Henz, A. Grützkau, U. Lippert, Y. Aragane, T. Schwarz, and S. Krüger-Krasagakes. 1998. Comparative cytokine gene expression: Regulation and release by human mast cells. Immunology 93:289–295.
Vergnolle, N., M. D. Hollenberg, K. A. Sharkey, and J. L. Wallace. 1999. Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Br. J. Pharmacol. 127:1083–1090.
Kawabata, A., R. Kuroda, T. Minami, K. Kataoka, and M. Taneda. 1998. Increased vascular permeability by a specific agonist of protease-activated receptor-2 in rat hindpaw. Br. J. Pharmacol. 125:419–422.
Coderre, T. J., A. I. Basbaum, and J. D. Levine. 1989. Neural control of vascular permeability: Interactions between primary afferents, mast cells, and sympathetic efferents. J. Neurophysiol. 62:48–58.
García, G., P. Brazís, N. Majó, L. Ferrer, F. de Mora, and A. Puigdemont. 1997. Comparative morphofunctional study of dispersed mature canine cutaneous mast cells and BR cells, a poorly differentiated mast cell line from dog subcutaneous mastocytoma. Vet. Immunol. Immunopathol. 62:323–337.
Leal-Berumen, I., P. Conlon, and J. S. Marshall. 1994. IL-6 production by rat peritoneal mast cells is not necessarily preceded by histamine release and can be induced by bacterial lipopolysaccharide. J. Immunol. 152:5468–5476.
Mazzari, S., R. Canella, L. Petrelli, G. Marcolongo, and A. Leon. 1996. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur. J. Pharmacol. 300:227–236.
Hultsch, T., K. D. Müller, J. G. Meingassner, M. Grassberger, R. E. Schopf, and J. Knop. 1998. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch. Dermatol. Res. 290:501–507.
Assanasen, P. and R. M. Naclerio. 2002. Antiallergic anti-inflammatory effects of H1-antihistamine in humans. Clin. Allergy Immunol. 17:101–139.
Queralt, M., C. Brazís, M. Merlos, and A. Puigdemont. 1998. Inhibitory effects of rupatadine on mast cell histamine release and skin wheal development induced by Ascaris suum in hypersensitive dogs. Drug Dev. Res. 44:49–55.
Ozaki, Y., J. Rui, Y. Tang, and M. Satake. 1997. Antiinflammatory effect of Forsythia suspense Vahl and its active fraction. Biol. Pharm. Bull. 20:861–864.
Janaki, S., V. Vijayasekaran, S. Viswanathan, and K. Balakrishna. 1999. Anti-inflammatory activity of Aglaia roxburghiana var. beddomei extract and trierpenes roxburghiadiol A and B. J. Ethnopharmacol. 67:45–51.
Moreno, L., R. Bello, E. Primo-Yufera, and J. Esplugues. 2002. Pharmacological properties of the methanol extract from Mentha suaveolens Ehrh. Phytother. Res. 1:S10-S13.
Lee, E. B., D. W. Li, J. E. Hyun, I. H. Kim, and W. K. Whang. 2001. Antiinflammatory activity of methanol extract of Kalopanax pictus bark and its fractions. J. Ethnopharmacol. 77:197–201.
Romagnani, S. 2000. The role of lymphocytes in allergic disease. J. Allergy Clin. Immunol. 105:399–408.
Romagnani, S. 2001. Cytokines and chemoattractants in allergic inflammation. Mol. Immunol. 38:881–885.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kim, MS., Na, HJ., Han, SW. et al. Forsythia fructus Inhibits the Mast-Cell-Mediated Allergic Inflammatory Reactions. Inflammation 27, 129–135 (2003). https://doi.org/10.1023/A:1023865727780
Issue Date:
DOI: https://doi.org/10.1023/A:1023865727780